Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

benzinga.com/news/health-care/25/10/48258803/johnson-johnsons-multiple-myeloma-patients

On Thursday, Johnson & Johnson (NYSE:JNJ) announced positive topline results from a recent study.
The company’s Phase 3 MajesTEC-3 trial is evaluating Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for patients with relapsed or…

This story appeared on benzinga.com, 2025-10-16 17:37:03.
The Entire Business World on a Single Page. Free to Use →